Literature DB >> 15007381

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Isabelle Bedrosian1, Karen H Lu, Claire Verschraegen, Khandan Keyomarsi.   

Abstract

We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007381     DOI: 10.1038/sj.onc.1207408

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Authors:  Rozita Bagheri-Yarmand; Anna Biernacka; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Authors:  Astrid M Eder; Xiaomei Sui; Daniel G Rosen; Laura K Nolden; Kwai Wa Cheng; John P Lahad; Madhuri Kango-Singh; Karen H Lu; Carla L Warneke; Edward N Atkinson; Isabelle Bedrosian; Khandan Keyomarsi; Wen-lin Kuo; Joe W Gray; Jerry C P Yin; Jinsong Liu; Georg Halder; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

Review 3.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

4.  Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Authors:  Said Akli; Xin-Qiao Zhang; Jolanta Bondaruk; Susan L Tucker; P Bogdan Czerniak; William F Benedict; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

Review 5.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

6.  Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

Authors:  Kimberly S Lucenay; Iman Doostan; Cansu Karakas; Tuyen Bui; Zhiyong Ding; Gordon B Mills; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2016-02-29       Impact factor: 12.701

7.  Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Authors:  Kelly K Hunt; Khandan Keyomarsi; Cansu Karakas; Min Jin Ha; Anna Biernacka; Min Yi; Aysegul A Sahin; Opoku Adjapong; Gabriel N Hortobagyi; Melissa Bondy; Patricia Thompson; Kwok Leung Cheung; Ian O Ellis; Sarah Bacus; W Fraser Symmans; Kim-Anh Do
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

8.  Expression of cyclin E in stage III colorectal carcinoma.

Authors:  Lea Rath-Wolfson; Michael Bergman; Yaacov Ori; Alex Goldman; Edward Ram; Rumelia Koren; Hertzel Salman
Journal:  Oncol Lett       Date:  2012-10-05       Impact factor: 2.967

9.  Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.

Authors:  Dariush Etemadmoghadam; Joshy George; Prue A Cowin; Carleen Cullinane; Maya Kansara; Kylie L Gorringe; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells.

Authors:  Nathan J Bowen; L DeEtte Walker; Lilya V Matyunina; Sanjay Logani; Kimberly A Totten; Benedict B Benigno; John F McDonald
Journal:  BMC Med Genomics       Date:  2009-12-29       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.